Released: November 20, 2026
Step 1 of 2
CAR T-cell therapy has transformed the treatment landscape for patients with relapsed/refractory multiple myeloma. As these therapies move earlier in the treatment course, healthcare professionals have an opportunity to improve outcomes for more patients. In this ClinicalThought, expert faculty share practical insights from clinical trials and real-world experience, including strategies for optimizing outcomes in older patients and those with high-risk disease or comorbidities. They also explore how emerging bispecific antibody combinations may influence treatment sequencing and highlight the importance of collaboration between community and academic centers to support patients throughout the CAR T-cell therapy journey.